ESG 206
Alternative Names: ESG-206Latest Information Update: 20 Jul 2024
At a glance
- Originator Shanghai Escugen Biotechnology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action B cell activating factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 31 May 2024 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) (IV) before May 2024 (NCT05263739)
- 31 May 2024 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in B-cell lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Jun 2023 Phase-I clinical trials in B-cell lymphoma in China (IV), prior to June 2023 (NCT05822843)